Patients
Following Institutional Review Board approval, we performed a retrospective analysis of all patients diagnosed with recurrent uLMS who presented to our institution from January 1, 2001 to January 1, 2020. All patients had previously undergone either total hysterectomy or radical hysterectomy or myomectomy at our center or an outside institution and diagnosed with uLMS after primary surgery which confirmed by an experienced gynecologic pathologist in our hospital. Only patients with first recurrent uLMS were included. Patients received treatment in the Department of Gynecological Oncology of Cancer Hospital, Chinese Academy of Medical Sciences, National Cancer Center.
The cohort was divided into two subgroups according to whether receive secondary cytoreductive surgery (SCS) for recurrent uLMS: the SCS subgroup, and non-SCS subgroup. The patients’ full medical records were included in this study. Clinical and pathologic variables, treatment modalities, and outcomes were assessed. Stage was retrospectively assigned using the International Federation of Gynecology and Obstetrics (FIGO) 2008 staging system for uterine sarcomas.